Written By VDCI Team
As of January 17, 2017, 47 out of 50 states and the District of Columbia have reported West Nile virus infections in people, birds, or mosquitoes in 2016. Overall, 2,038 cases of WNV were reported in humans, and there were 94 confirmed deaths (4.61%) in 2016. The total is a slight improvement from 2015, where there were 2,060 human cases and 119 confirmed deaths (5.8%). To learn more about the symptoms, treatment, and mosquito species that vector this virus, visit our educational page on West Nile virus.
Eastern equine encephalitis (EEE): EEE, also referred to as Triple E, is a rare but deadly illness for humans. Thankfully, only a few human cases of EEE are reported in the United States each year. From 2004 to 2013, an average of eight cases of EEE were reported annually in the U.S. The reason EEE is less common in humans is that the primary mosquito vector (Culiseta melanura), does not typically feed on humans. It is believed that EEE virus is mainly transmitted to humans and horses by bridge vectors that have contracted the virus by feeding on infected birds. Symptoms typically occur four to ten days after a bite from an infected mosquito and include fever, headache, vomiting, muscle aches, joint pain, and fatigue. In rare cases, infection occurs in the brain and spinal cord leading to sudden high fever, stiff neck, disorientation, seizures, and coma. The mortality rate of those that develop EEE is about 33%, the highest among human arboviruses (a virus transmitted by arthropod vectors) cases reported in the U.S. Currently, there is no human vaccine for EEE. The disease is also a concern for horses; however, a vaccine is available for horse owners.
Although preliminary, five human cases of EEE were reported nationally in 2016. In 2015, there were six reported human cases of EEE and 50% of those cases were fatal. To learn more about the symptoms, treatment, and mosquito species that vector this virus, visit our educational page on EEE virus.
Zika Virus (ZIKV): The Zika virus has been prevalent in the news in 2016, but has actually been around since 1947. In the Americas, it has only been linked to transmission by Aedes aegypti. Ae. aegypti is also responsible for the transmission of dengue virus, yellow fever virus, and chikungunya virus. Recently in Africa, the virus was detected in Aedes albopictus or the Asian tiger mosquito; hence, it is possible that Ae. albopictus could vector the virus in the Americas. If a pregnant woman is infected with Zika virus, it may result in microcephaly, a birth defect causing underdevelopment of the head and brain in newborn children. When symptoms occur, they typically begin with a mild headache and fever. Within a day or two, a maculopapular rash may appear and can cover many parts of the body. Following the rash, people generally report continued fever, malaise, and body aches. Other symptoms can include diarrhea, constipation, abdominal pain, and dizziness. Treatment for symptoms includes hydration, rest, and the use of acetaminophen to relieve fever. Currently, there is no vaccine or cure for ZIKV.
As of January 4, 2017, within the U.S., there were 216 cases of ZIKV locally and 4,619 travel associated cases reported to the CDC in 2016. The 216 local cases, from the states of Florida and Texas, have received the most attention from the U.S. media. The U.S. territories (Puerto Rico, U.S. Virgin Islands, and several other U.S. territories) experienced a total of 35,021 locally-acquired cases were reported in 2016. VDCI partnered with the CDC in several U.S. territories in 2016 to help combat the spread of Zika virus and will continue to work with the CDC in 2017 to protect public health. To learn more about the symptoms, treatment, and mosquito species that vector this virus, visit our educational page on Zika virus.
VDCI is committed to public education and spreading awareness throughout the U.S. about the dangers of mosquito-borne diseases and their preventability, with the overarching goal of reducing illness and fatality statistics in 2017. Our dedicated and experienced team works tirelessly to prevent the spread of mosquito-borne diseases in all of the contracts we service. If you would like more information about any aspect of an Integrated Mosquito Management (IMM) Plan, including mosquito surveillance, disease testing, or adult control, please contact Vector Disease Control International (VDCI), and we will help you get started immediately.
Since 1992, Vector Disease Control International (VDCI) has taken pride in providing municipalities, mosquito abatement districts, military bases, industrial sites, planned communities, homeowners associations, and golf courses with the tools they need to run effective integrated tick and mosquito management. We are determined to protect the public health of the communities in which we operate. Our tick and mosquito management professionals have over 100 years of combined experience in the field of public health, specifically vector disease control. We strive to provide the most effective and scientifically sound mosquito surveillance and control programs possible based on an Integrated Mosquito Management approach recommended by the American Mosquito Control Association (AMCA) and Centers for Disease Control and Prevention (CDC). VDCI is the only company in the country that can manage all aspects of an integrated tick and mosquito management program, from surveillance to disease testing to mosquito aerial application in emergency response situations.
Contact the professionals at 800.413.4445 for all of your integrated tick and mosquito management needs.